We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medidata Clinical Cloud Selected for AML Master Trial by LLS
Read MoreHide Full Article
Medidata Solutions Inc. recently announced that The Leukemia & Lymphoma Society (“LLS”) has selected its flagship Medidata Clinical Cloud platform for diagnosis and treatment of acute myeloid leukemia (AML) through a clinical trial known as the ‘Beat AML Master Trial’. We note that LLS is the world's largest voluntary health organization dedicated to funding blood cancer research.
Per management, the Beat AML Master Trial is a great example of a precision medicine that leverages on the Medidata Patient Cloud platform. Interestingly, Medidata Cloud addressed over 800 life sciences companies in the last reported quarter and gave them an integrated platform to meet the future development needs.
Getting back to the news, Medidata has been working closely with INC Research to deploy solutions across all research sites participating in the Beat AML Master Trial. These solutions included Medidata Coder, and Medidata Rave – the company’s integrated solution for electronic data capture, management and report.
Headquartered in New York, Medidata is a pioneer in global drug development techniques, courtesy of its highly advanced cloud-based solutions for clinical research.
Of late, the company gained a lot of prominence in the niche markets leveraging on its diversified product portfolio, which includes highly exclusive products like Image Management, Risk-Based Monitoring, Medidata Balance, Medidata CTMS and Medidata Patient Cloud.
Stock Performance
Medidata’s price performance has been encouraging.
Over the past one year, the stock represented a stellar return of almost 54.4%, outshining the Zacks classified Medical Information Systems sub-industry’s loss of 3.7%. Furthermore, the current return of the stock is well ahead of the S&P 500’s return of 13.6% over the same time frame.
Coming to the estimate revision trend of Medidata, two estimates moved north in the last two months compared to no movement downward for the full year. As a result, the current year estimates inched up 0.8% to 75 cents per share, over the same time frame.
The bullish analyst sentiments justify the stock’s Zacks Rank #2 (Buy).
Our Take
The Cancer/Tumor Profiling market has good prospects as it is forecast to reach a worth of $35 billion by 2018, growing at a CAGR of 18.5% (Companies and markets.). This highlights the potential of Medidata’s Clinical Cloud platform in the market for cancer and tumor treatment in the coming quarters.
Also, a long-term expected earnings growth rate of 21.67% and a projected sales growth of 18.95% instill confidence on the stock.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 86.2%.
Avinger projects sales growth of 30.6% for the current year. Additionally, the company has projected earnings per share growth rate of 39.53% for the current year.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock posted a positive earnings surprise of 1.6% in the last reported quarter.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medidata Clinical Cloud Selected for AML Master Trial by LLS
Medidata Solutions Inc. recently announced that The Leukemia & Lymphoma Society (“LLS”) has selected its flagship Medidata Clinical Cloud platform for diagnosis and treatment of acute myeloid leukemia (AML) through a clinical trial known as the ‘Beat AML Master Trial’. We note that LLS is the world's largest voluntary health organization dedicated to funding blood cancer research.
Per management, the Beat AML Master Trial is a great example of a precision medicine that leverages on the Medidata Patient Cloud platform. Interestingly, Medidata Cloud addressed over 800 life sciences companies in the last reported quarter and gave them an integrated platform to meet the future development needs.
Getting back to the news, Medidata has been working closely with INC Research to deploy solutions across all research sites participating in the Beat AML Master Trial. These solutions included Medidata Coder, and Medidata Rave – the company’s integrated solution for electronic data capture, management and report.
Medidata Solutions, Inc. Price
Medidata Solutions, Inc. Price | Medidata Solutions, Inc. Quote
Headquartered in New York, Medidata is a pioneer in global drug development techniques, courtesy of its highly advanced cloud-based solutions for clinical research.
Of late, the company gained a lot of prominence in the niche markets leveraging on its diversified product portfolio, which includes highly exclusive products like Image Management, Risk-Based Monitoring, Medidata Balance, Medidata CTMS and Medidata Patient Cloud.
Stock Performance
Medidata’s price performance has been encouraging.
Over the past one year, the stock represented a stellar return of almost 54.4%, outshining the Zacks classified Medical Information Systems sub-industry’s loss of 3.7%. Furthermore, the current return of the stock is well ahead of the S&P 500’s return of 13.6% over the same time frame.
Coming to the estimate revision trend of Medidata, two estimates moved north in the last two months compared to no movement downward for the full year. As a result, the current year estimates inched up 0.8% to 75 cents per share, over the same time frame.
The bullish analyst sentiments justify the stock’s Zacks Rank #2 (Buy).
Our Take
The Cancer/Tumor Profiling market has good prospects as it is forecast to reach a worth of $35 billion by 2018, growing at a CAGR of 18.5% (Companies and markets.). This highlights the potential of Medidata’s Clinical Cloud platform in the market for cancer and tumor treatment in the coming quarters.
Also, a long-term expected earnings growth rate of 21.67% and a projected sales growth of 18.95% instill confidence on the stock.
Stocks to Consider
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corporation . Notably, Inogen sports a Zacks Rank #1 (Strong Buy) while Fluidigm and Avinger carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 86.2%.
Avinger projects sales growth of 30.6% for the current year. Additionally, the company has projected earnings per share growth rate of 39.53% for the current year.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock posted a positive earnings surprise of 1.6% in the last reported quarter.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>